Cullinan Therapeutics CLN-049 Receives FDA Orphan Drug Designation
Cullinan Therapeutics announced that the FDA has granted orphan drug designation to CLN-049, a novel, investigational FLT3xCD3 T cell engager, for the treatment of relapsed/refractory acute myeloid leukemia.
